Buyout candidate? . . . Absolutely
CEO Marc Beer built and sold ViaCell to PerkinElmer, and prior to that he was a VP at Genzyme. He knows the game. If this drug gets FDA approval on December 29, I doubt that AEGR stays independent for long. High-buck drugs for rare diseases are in high demand, and AEGR's proven pipeline would make it a truly hot prospect.